By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Moderna Therapeutics, Inc. 

320 Bent Street

Cambridge  Massachusetts  02141  U.S.A.
Phone: 617-714-6500 Fax: 617-583-1998


At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.

We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.

Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.

Key Statistics

Ownership: Private

Web Site: Moderna


Company News
AstraZeneca PLC (AZN) Wagers Another $140 Million on Biotech 'Unicorn' Moderna 8/10/2016 9:47:32 AM
Flushed With Cash, Moderna Expands Space, Went on Hiring Spree and Launches at Least Two Clinical Trials 7/26/2016 5:52:24 AM
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology 7/6/2016 6:25:31 AM
Merck & Co. (MRK) And Moderna Announce Strategic Collaboration To Advance Novel Mrna-Based Personalized Cancer Vaccines With KEYTRUDA(Pembrolizumab) For The Treatment Of Multiple Types Of Cancer 6/29/2016 9:31:04 AM
Moderna Gets Upfront $200M Cash, Ties New Cancer Pact With Merck & Co. (MRK) 6/29/2016 7:20:54 AM
Moderna And Charles River Laboratories (CRL) Announce Strategic Collaboration To Scale Moderna’s Nonclinical Development Efforts For Novel mRNA Therapeutics 6/6/2016 8:19:33 AM
Moderna Announces Appointment Of Dr. Michael Watson As President Of Valera Pharmaceuticals (VLRX) 4/4/2016 11:22:40 AM
Moderna Appoints Saqib Islam As Chief Business Officer 3/28/2016 10:18:10 AM
Moderna Announces Transition To A Clinical Stage Company, Provides Business Update And Outlines 2016 Strategic Priorities 1/12/2016 12:15:46 PM
Moderna, Through Valera, Its Infectious Disease Venture, Announces Initial Grant Of Up To $20 Million To Advance mRNA-Based Antibody Combination To Help Prevent HIV Infection 1/12/2016 11:51:52 AM